ALZECURE PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 SEK | -2.78% |
|
-13.37% | -43.73% |
| Apr. 25 | AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 10 | Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR). | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 154.8 | 342.2 | 224.7 | 257 | 193.1 | 108.7 | - |
| Enterprise Value (EV) 1 | 154.8 | 342.2 | 183 | 257 | 164 | 66.15 | 108.7 |
| P/E ratio | -3.04 x | -4.79 x | -2.89 x | -3.51 x | - | 5.83 x | -1.59 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 1,810,871 x |
| EV / Revenue | - | - | - | - | - | - | 1,810,871 x |
| EV / EBITDA | - | - | -2.37 x | - | -4.34 x | -1.42 x | -15.5 x |
| EV / FCF | - | - | - | - | 53.6 x | 3.89 x | -1.67 x |
| FCF Yield | - | - | - | - | 1.86% | 25.7% | -59.8% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 37,766 | 37,766 | 37,766 | 62,087 | 62,087 | 62,087 | - |
| Reference price 2 | 4.100 | 9.060 | 5.950 | 4.140 | 3.110 | 1.750 | 1.750 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/24/23 | 2/27/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.00006 |
| EBITDA 1 | - | - | -77.35 | - | -37.79 | -46.5 | -7 |
| EBIT 1 | - | - | -77.93 | - | -38.26 | -46.5 | -7 |
| Operating Margin | - | - | - | - | - | - | -11,666,666.67% |
| Earnings before Tax (EBT) 1 | - | - | -77.78 | - | -37.17 | -46.5 | -7 |
| Net income 1 | -50.86 | -71.37 | -77.78 | -56.24 | -37.17 | -46.5 | -7 |
| Net margin | - | - | - | - | - | - | -11,666,666.67% |
| EPS 2 | -1.350 | -1.890 | -2.060 | -1.180 | - | 0.3000 | -1.100 |
| Free Cash Flow 1 | - | - | - | - | 3.057 | 17 | -65 |
| FCF margin | - | - | - | - | - | - | -108,333,333.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/24/23 | 2/27/24 | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 41.7 | - | 29.1 | 42.5 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 3.06 | 17 | -65 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | 0.05 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/26/21 | 2/24/22 | 2/24/23 | 2/27/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -43.73% | 10.06M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- ALZCUR Stock
- Financials AlzeCure Pharma AB
